Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1

Futu NewsNov 20 01:31 · Ratings

BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating

Futu NewsNov 15 22:33 · Ratings

Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)

TipRanksNov 15 22:25 · Ratings

BioXcel Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.

BenzingaNov 15 04:17

BioXcel Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 14 22:17 · Announcements

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 14 22:16 · Conference Call